The Industrialization of Nucleic Acid QC

Automated Capillary Electrophoresis for DNA and RNA Analysis

The Agilent Fragment Analyzer automates a previously manual, low-throughput step: sizing and quantifying DNA, RNA, and NGS library fragments. By running 12 to 96 samples in parallel on a single system, it collapses what once took hours into under sixty minutes.

This speed matters less for individual researchers than for centralized sequencing facilities processing hundreds of libraries daily. The instrument’s value lies in standardization—removing operator variability from fragment analysis and producing reproducible data across runs and sites.

For labs handling cell-free DNA, PCR products, or RNA integrity checks, the trade-off is clear: higher upfront capital outlay for reduced per-sample labor and faster turnaround. That calculus increasingly favors automation as sample volumes rise.

China’s genomics sector, dominated by large-scale sequencing centers and biobanks, is a natural market for such systems. Domestic manufacturers are now developing competing capillary electrophoresis platforms, though they have yet to match the throughput consistency of established Western instruments.

The Fragment Analyzer reveals a broader trend: the molecular biology lab is becoming a production floor. Instruments that eliminate manual QC steps are not luxuries—they are prerequisites for scaling genomic medicine.

Why it matters:
For buyers, the choice is between buying a system that integrates into existing automation pipelines or building manual processes that become bottlenecks at scale. The Fragment Analyzer’s real advantage is not speed alone, but the operational predictability it enforces.

View Product →